Abstract
Dopamine (DA), the most abundant catecholamine in the basal ganglia, participates in the regulation of motor functions and of cognitive processes such as learning and memory. Abnormalities in dopaminergic systems are thought to be the bases for some neuropsychiatric disorders including addiction, Parkinson’s disease, and Schizophrenia. DA exerts its arrays of functions via stimulation of D1-like (D1 and D5) and D2-like (D2, D3, and D4) DA receptors which are located in various regions of the brain. The DA D1 and D2 receptors are very abundant in the basal ganglia where they exert their functions within separate neuronal cell types. The present paper focuses on a review of the effects of stimulation of DA D1 receptors on diverse signal transduction pathways and gene expression patterns in the brain. We also discuss the possible involvement of the DA D1 receptors in DA-mediated toxic effects observed both in vitro and in vivo. Future studies using more selective agonist and antagonist agents and the use of genetically modified animals should help to further clarify the role of these receptors in the normal physiology and in pathological events that involve DA.
Keywords: Amphetamines, AP-1, apoptosis, basal ganglia, cocaine, DA receptors, Egr, signal transduction.
CNS & Neurological Disorders - Drug Targets
Title: Dopamine D1 Receptors, Regulation of Gene Expression in the Brain, and Neurodegeneration
Volume: 9 Issue: 5
Author(s): Jean Lud Cadet, Subramaniam Jayanthi, Michael T. McCoy, Genevieve Beauvais and Ning Sheng Cai
Affiliation:
Keywords: Amphetamines, AP-1, apoptosis, basal ganglia, cocaine, DA receptors, Egr, signal transduction.
Abstract: Dopamine (DA), the most abundant catecholamine in the basal ganglia, participates in the regulation of motor functions and of cognitive processes such as learning and memory. Abnormalities in dopaminergic systems are thought to be the bases for some neuropsychiatric disorders including addiction, Parkinson’s disease, and Schizophrenia. DA exerts its arrays of functions via stimulation of D1-like (D1 and D5) and D2-like (D2, D3, and D4) DA receptors which are located in various regions of the brain. The DA D1 and D2 receptors are very abundant in the basal ganglia where they exert their functions within separate neuronal cell types. The present paper focuses on a review of the effects of stimulation of DA D1 receptors on diverse signal transduction pathways and gene expression patterns in the brain. We also discuss the possible involvement of the DA D1 receptors in DA-mediated toxic effects observed both in vitro and in vivo. Future studies using more selective agonist and antagonist agents and the use of genetically modified animals should help to further clarify the role of these receptors in the normal physiology and in pathological events that involve DA.
Export Options
About this article
Cite this article as:
Lud Cadet Jean, Jayanthi Subramaniam, T. McCoy Michael, Beauvais Genevieve and Sheng Cai Ning, Dopamine D1 Receptors, Regulation of Gene Expression in the Brain, and Neurodegeneration, CNS & Neurological Disorders - Drug Targets 2010; 9 (5) . https://dx.doi.org/10.2174/187152710793361496
DOI https://dx.doi.org/10.2174/187152710793361496 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Defining the Mechanism of Action of 4-Phenylbutyrate to Develop a Small-Molecule-Based Therapy for Alzheimers Disease
Current Medicinal Chemistry Metal and Inflammatory Targets for Alzheimers Disease
Current Drug Targets Induced Adaptive Resistance to Oxidative Stress in the CNS: A Discussion on Possible Mechanisms and Their Therapeutic Potential
Current Drug Metabolism Molecular Targeted Approaches for Treatment of Pancreatic Cancer
Current Pharmaceutical Design Recent Therapeutic Advances for Treating Medulloblastoma: Focus on New Molecular Targets
CNS & Neurological Disorders - Drug Targets Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase
Anti-Cancer Agents in Medicinal Chemistry The Proteasome in Health and Disease
Current Pharmaceutical Design Genetics of Bladder Malignant Tumors in Childhood
Current Genomics Theories and Treatment of Drug Dependency: A Neurochemical Perspective
Current Molecular Pharmacology NPY and NPY Receptors in Vascular Remodeling
Current Topics in Medicinal Chemistry The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology DYRK1A Kinase Inhibitors with Emphasis on Cancer
Mini-Reviews in Medicinal Chemistry Modulation of the Intrinsic Properties of Motoneurons by Serotonin
Current Pharmaceutical Design The Ubiquitin-Proteasome System as a Prospective Molecular Target for Cancer Treatment and Prevention
Current Protein & Peptide Science Antiproliferative Activity of Cobra Venom Cytotoxins
Current Topics in Medicinal Chemistry Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Inflammatory Mechanisms and Oxidative Stress as Key Factors Responsible for Progression of Neurodegeneration: Role of Brain Innate Immune System
CNS & Neurological Disorders - Drug Targets